Abstract
We analyzed the evolution of viral tropism after 8 days of maraviroc monotherapy, i.e., we used the maraviroc clinical test (MCT), in 21 patients with and 14 without virological response to the drug (MCT(+) and MCT(-) patients, respectively). No increases in CXCR4 inferred viral loads (X4IVLs) were observed in MCT(+) patients, while X4IVLs increased only in MCT(-) patients, with X4IVLs of >2 log(10) HIV RNA copies/ml. These results shed light on the evolution of viral tropism under a CCR5 antagonist in vivo.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-HIV Agents / therapeutic use*
-
CCR5 Receptor Antagonists
-
CD4-Positive T-Lymphocytes / metabolism
-
Cyclohexanes / therapeutic use*
-
HIV Infections / drug therapy*
-
HIV Infections / metabolism
-
HIV Infections / virology*
-
Humans
-
Maraviroc
-
Receptors, CXCR4 / metabolism
-
Triazoles / therapeutic use*
-
Viral Load / drug effects
Substances
-
Anti-HIV Agents
-
CCR5 Receptor Antagonists
-
CXCR4 protein, human
-
Cyclohexanes
-
Receptors, CXCR4
-
Triazoles
-
Maraviroc